Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.50) by 30 percent. This is a 94.44 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $16.352 million which beat the analyst consensus estimate of $12.609 million by 29.69 percent.